Amgen sued over experimental Parkinson's drug

In an unusual court case, two people are suing Amgen for the right to use an experimental Parkinson's drug that the biotech concluded could be dangerous to their health. The case revolves around GDNF, which Amgen shelved after examining trial data last year. Amgen's attorney told a federal judge that the drug represented an unreasonable risk. But two Parkinson's patients who took the drug insist that it could be their only hope for improving their condition.

- read the story from the Los Angeles Times for more


Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.